APYX
Apyx Medical CorporationNASDAQHealthcare$3.68+1.38%ClosedMarket Cap: $153.9M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
10.67
P/S
2.91
EV/EBITDA
-33.15
DCF Value
$-4.62
FCF Yield
-5.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
36.0%
Operating Margin
-12.2%
Net Margin
-21.2%
ROE
-117.5%
ROA
-16.8%
ROIC
-11.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $19.2M | -10.5% | $11.0K | $-1.3M | $-0.03 | — |
| FY 2025 | $52.8M | 36.0% | $-6.4M | $-11.2M | $-0.27 | — |
| Q3 2025 | $12.9M | 64.4% | $-832.0K | $-2.0M | $-0.05 | — |
| Q2 2025 | $11.4M | 62.3% | $-2.6M | $-3.8M | $-0.09 | — |
| Q1 2025 | $9.4M | 60.1% | $-3.1M | $-4.2M | $-0.12 | — |
| Q4 2024 | $14.2M | 63.0% | $-3.0M | $-4.6M | $-0.12 | — |
| FY 2024 | $48.1M | 61.0% | $-18.8M | $-23.5M | $-0.66 | — |
| Q3 2024 | $11.5M | 60.5% | $-3.6M | $-4.7M | $-0.14 | — |
| Q2 2024 | $12.1M | 23.1% | $-5.5M | $-6.6M | $-0.19 | — |
| Q1 2024 | $10.2M | 58.1% | $-6.6M | $-7.6M | $-0.22 | — |
| Q4 2023 | $14.7M | 27.7% | $-5.8M | $-9.6M | $-0.28 | — |
| FY 2023 | $52.3M | 64.5% | $-17.3M | $-18.7M | $-0.54 | — |